OpGen (OPGN): תחזית צמיחת רווחים לשנה הבאה

OpGen, Inc. (OPGN) develops molecular analysis systems to combat antibiotic resistance. Analyst 12-month EPS growth targets confirm a crisis, where 0.00 reflects the metric's baseline. The Unyvero IT platform integrated rapid tests with AI databases, but the company is currently liquidating assets due to the bankruptcy of its European divisions and the failure to commercialize its developments.

This indicator measures the dynamics of consensus earnings forecasts for the coming year, reflecting the amplitude of shifts in market expectations and the degree of transparency in corporate reporting. By analyzing the growth rate model for next year's earnings, an investor can assess volatility risks in demand for OpGen, Inc. (OPGN) molecular diagnostic systems and tests, where sharp fluctuations in the metric signal uncertainty regarding commercial prospects.